دورية أكاديمية
أعرض في EDS

Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature.

التفاصيل البيبلوغرافية
العنوان: Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature.
المؤلفون: Li Y; School of Biology and Engineering, Guizhou Medical University, Guiyang, Guizhou, China., Su H; School of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China., Liu K; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China., Zhao Z; The Sino-Russian Medical Research Center of Jinan University, The Institute of Chronic Disease of Jinan University, The First Affiliated Hospital of Jinan University, Guangzhou, China., Wang Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China., Chen B; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China., Xia J; School of Biology and Engineering, Guizhou Medical University, Guiyang, Guizhou, China., Yuan H; School of Biology and Engineering, Guizhou Medical University, Guiyang, Guizhou, China., Huang DS; Bioinformatics and BioMedical Bigdata Mining Laboratory, School of Big Health, Guizhou Medical University, Guiyang, Guizhou, China. 4660094239@qq.com., Gu Y; College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China. guyunyan@ems.hrbmu.edu.cn.
المصدر: World journal of surgical oncology [World J Surg Oncol] 2024 Feb 09; Vol. 22 (1), pp. 49. Date of Electronic Publication: 2024 Feb 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7819 (Electronic) Linking ISSN: 14777819 NLM ISO Abbreviation: World J Surg Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, 2003-
مواضيع طبية MeSH: Transcriptome* , Prostatic Neoplasms*/drug therapy, Male ; Humans ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/metabolism ; Oncogene Proteins, Fusion/therapeutic use ; RNA, Messenger/genetics ; Transcriptional Regulator ERG/genetics ; Transcriptional Regulator ERG/metabolism ; Serine Endopeptidases/genetics ; Serine Endopeptidases/metabolism ; Serine Endopeptidases/therapeutic use
مستخلص: Background: TMPRSS2-ERG (T2E) fusion is highly related to aggressive clinical features in prostate cancer (PC), which guides individual therapy. However, current fusion prediction tools lacked enough accuracy and biomarkers were unable to be applied to individuals across different platforms due to their quantitative nature. This study aims to identify a transcriptome signature to detect the T2E fusion status of PC at the individual level.
Methods: Based on 272 high-throughput mRNA expression profiles from the Sboner dataset, we developed a rank-based algorithm to identify a qualitative signature to detect T2E fusion in PC. The signature was validated in 1223 samples from three external datasets (Setlur, Clarissa, and TCGA).
Results: A signature, composed of five mRNAs coupled to ERG (five ERG-mRNA pairs, 5-ERG-mRPs), was developed to distinguish T2E fusion status in PC. 5-ERG-mRPs reached 84.56% accuracy in Sboner dataset, which was verified in Setlur dataset (n = 455, accuracy = 82.20%) and Clarissa dataset (n = 118, accuracy = 81.36%). Besides, for 495 samples from TCGA, two subtypes classified by 5-ERG-mRPs showed a higher level of significance in various T2E fusion features than subtypes obtained through current fusion prediction tools, such as STAR-Fusion.
Conclusions: Overall, 5-ERG-mRPs can robustly detect T2E fusion in PC at the individual level, which can be used on any gene measurement platform without specific normalization procedures. Hence, 5-ERG-mRPs may serve as an auxiliary tool for PC patient management.
(© 2024. The Author(s).)
References: BMC Genomics. 2018 Jan 29;19(1):99. (PMID: 29378509)
Am J Surg Pathol. 2011 Jul;35(7):1014-20. (PMID: 21677539)
J Cell Biol. 2022 Jun 6;221(6):. (PMID: 35446349)
Br J Cancer. 2022 Sep;127(5):916-926. (PMID: 35618786)
BMJ. 2004 May 1;328(7447):1073. (PMID: 15117797)
Mol Biol Rep. 2023 Nov;50(11):9307-9314. (PMID: 37812356)
Nature. 2009 Nov 5;462(7269):108-12. (PMID: 19847166)
iScience. 2021 Sep 17;24(10):103135. (PMID: 34622176)
Nat Biotechnol. 2021 May;39(5):599-608. (PMID: 33462507)
Actas Urol Esp. 2011 Jul-Aug;35(7):420-8. (PMID: 21601955)
Front Public Health. 2022 Jul 12;10:935521. (PMID: 35903379)
Mol Oncol. 2022 Aug;16(16):3034-3051. (PMID: 35810469)
Front Immunol. 2019 Sep 26;10:2293. (PMID: 31616443)
Cancer Med. 2021 May;10(9):3129-3138. (PMID: 33769705)
Sci Rep. 2023 Oct 18;13(1):17719. (PMID: 37853026)
Environ Sci Pollut Res Int. 2020 Feb;27(5):4969-4975. (PMID: 31845254)
Biomed Res Int. 2013;2013:465179. (PMID: 23781502)
Science. 2019 May 3;364(6439):485-491. (PMID: 31048490)
Life (Basel). 2021 Jun 21;11(6):. (PMID: 34205581)
Sci Rep. 2021 Aug 18;11(1):16797. (PMID: 34408231)
Int J Mol Sci. 2022 Apr 26;23(9):. (PMID: 35563163)
Cell. 2021 Jun 24;184(13):3573-3587.e29. (PMID: 34062119)
Cancer Biol Med. 2021 Feb 15;18(1):245-255. (PMID: 33628598)
Nat Commun. 2020 May 8;11(1):2285. (PMID: 32385277)
Life Sci. 2020 Feb 1;242:117223. (PMID: 31881222)
Clin Transl Med. 2020 Dec;10(8):e216. (PMID: 33377652)
Bioinformatics. 2015 Jan 1;31(1):62-8. (PMID: 25165092)
Blood Cancer J. 2017 Jul 14;7(7):e583. (PMID: 28708130)
Front Oncol. 2022 Nov 10;12:950094. (PMID: 36439479)
Artif Cells Nanomed Biotechnol. 2017 Dec;45(8):1612-1619. (PMID: 28058860)
Anticancer Res. 2016 Sep;36(9):4787-93. (PMID: 27630329)
Cell Rep. 2017 Jan 3;18(1):248-262. (PMID: 28052254)
Cancer Cell Int. 2018 Nov 12;18:177. (PMID: 30459527)
Nucleic Acids Res. 2017 Jan 4;45(D1):D784-D789. (PMID: 27899563)
BJU Int. 2014 Feb;113(2):309-19. (PMID: 24006850)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
Gene. 2018 Mar 1;645:69-75. (PMID: 29277318)
Commun Biol. 2020 Dec 16;3(1):778. (PMID: 33328604)
J Biol Chem. 2022 Nov;298(11):102546. (PMID: 36181793)
Nucleic Acids Res. 2020 Nov 4;48(19):e113. (PMID: 32997146)
Science. 2005 Oct 28;310(5748):644-8. (PMID: 16254181)
Cancer Cell Int. 2021 Dec 14;21(1):669. (PMID: 34906147)
Nanomaterials (Basel). 2022 Mar 27;12(7):. (PMID: 35407220)
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4482-7. (PMID: 27044116)
J Natl Cancer Inst. 2008 Jun 4;100(11):815-25. (PMID: 18505969)
Front Oncol. 2022 Jun 23;12:918780. (PMID: 35814387)
معلومات مُعتمدة: 32270710 National Natural Science Foundation of China
فهرسة مساهمة: Keywords: 5-ERG-mRPs; Cross-platform; Prostate cancer; Qualitative signature; TMPRSS2-ERG fusion
المشرفين على المادة: 0 (Oncogene Proteins, Fusion)
0 (RNA, Messenger)
0 (ERG protein, human)
0 (Transcriptional Regulator ERG)
EC 3.4.21.- (TMPRSS2 protein, human)
EC 3.4.21.- (Serine Endopeptidases)
0 (TMPRSS2-ERG fusion protein, human)
تواريخ الأحداث: Date Created: 20240208 Date Completed: 20240214 Latest Revision: 20240214
رمز التحديث: 20240214
مُعرف محوري في PubMed: PMC10854045
DOI: 10.1186/s12957-024-03314-8
PMID: 38331878
قاعدة البيانات: MEDLINE
الوصف
تدمد:1477-7819
DOI:10.1186/s12957-024-03314-8